Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis

Summary

ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5 days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary Langerhans cell histiocytosis and impairment of lung function patients.

Timeline

Start

2011-11

Primary completion

2018-04

Completion

2022-04

Publications

• Benattia A, Lorillon G, de Margerie-Mellon C, Vercellino L, Bonniaud P, Marquette CH, Chevret S, Tazi A. Efficacy and safety of cladribine in adult pulmonary Langerhans cell histiocytosis: a phase II study. Eur Respir J. 2026 May 21;67(5):2501464. doi: 10.1183/13993003.01464-2025. Print 2026 May.

Drugs

Indications